Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(4.02)
# 1,678
Out of 4,396 analysts
75
Total ratings
44.6%
Success rate
13.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Maintained: Buy | $100 | $31.81 | +214.37% | 10 | Jun 4, 2026 | |
| AXSM Axsome Therapeutics | Maintained: Buy | $220 → $272 | $245.64 | +10.73% | 5 | May 4, 2026 | |
| ALEC Alector | Upgraded: Buy | n/a | $1.63 | - | 3 | Apr 15, 2026 | |
| RZLT Rezolute | Maintained: Hold | n/a | $3.90 | - | 6 | Mar 25, 2026 | |
| ALKS Alkermes | Maintained: Buy | $43 | $44.29 | -2.91% | 1 | Mar 11, 2026 | |
| NVAX Novavax | Maintained: Buy | $18 | $8.67 | +107.61% | 2 | Jan 13, 2026 | |
| CRVO CervoMed | Initiated Coverage: Buy | n/a | $2.89 | - | 1 | Dec 18, 2025 | |
| HELP Cybin | Reiterated: Buy | n/a | $3.92 | - | 1 | Oct 15, 2025 | |
| DNTH Dianthus Therapeutics | Reiterated: Buy | n/a | $84.57 | - | 2 | Aug 22, 2025 | |
| ELDN Eledon Pharmaceuticals | Reiterated: Buy | n/a | $3.55 | - | 5 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.466 | - | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $97.20 | - | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $7.16 | - | 7 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.20 | n/a | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $1.19 | n/a | 8 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $3.43 | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 | $3.82 | n/a | 4 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $2.19 | n/a | 3 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $18.39 | n/a | 3 | Jun 23, 2023 |
Vera Therapeutics
Jun 4, 2026
Maintained: Buy
Price Target: $100
Current: $31.81
Upside: +214.37%
Axsome Therapeutics
May 4, 2026
Maintained: Buy
Price Target: $220 → $272
Current: $245.64
Upside: +10.73%
Alector
Apr 15, 2026
Upgraded: Buy
Price Target: n/a
Current: $1.63
Upside: -
Rezolute
Mar 25, 2026
Maintained: Hold
Price Target: n/a
Current: $3.90
Upside: -
Alkermes
Mar 11, 2026
Maintained: Buy
Price Target: $43
Current: $44.29
Upside: -2.91%
Novavax
Jan 13, 2026
Maintained: Buy
Price Target: $18
Current: $8.67
Upside: +107.61%
CervoMed
Dec 18, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $2.89
Upside: -
Cybin
Oct 15, 2025
Reiterated: Buy
Price Target: n/a
Current: $3.92
Upside: -
Dianthus Therapeutics
Aug 22, 2025
Reiterated: Buy
Price Target: n/a
Current: $84.57
Upside: -
Eledon Pharmaceuticals
Jul 10, 2025
Reiterated: Buy
Price Target: n/a
Current: $3.55
Upside: -
Jul 7, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.466
Upside: -
Jul 2, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $97.20
Upside: -
Jul 1, 2025
Reiterated: Buy
Price Target: n/a
Current: $7.16
Upside: -
May 13, 2025
Reiterated: Buy
Price Target: n/a
Current: $5.20
Upside: n/a
Mar 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $1.19
Upside: n/a
Jan 10, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $3.43
Upside: n/a
Aug 8, 2023
Reiterated: Buy
Price Target: $34
Current: $3.82
Upside: n/a
Aug 8, 2023
Reiterated: Buy
Price Target: $13
Current: $2.19
Upside: n/a
Jun 23, 2023
Rated: Hold
Price Target: n/a
Current: $18.39
Upside: n/a